enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Company profile
Ticker
ENTA
Exchange
Website
CEO
Jay Luly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Enanta Pharmaceuticals Security Corporation ...
ENTA stock data
Latest filings (excl ownership)
S-3
Shelf registration
22 Nov 23
10-K
2023 FY
Annual report
22 Nov 23
POSASR
Automatic shelf registration (post-effective amendment)
22 Nov 23
8-K
Results of Operations and Financial Condition
20 Nov 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
8-K
Results of Operations and Financial Condition
7 Aug 23
8-K
Regulation FD Disclosure
7 Jun 23
10-Q
2023 Q2
Quarterly report
9 May 23
8-K
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
8 May 23
Transcripts
ENTA
Earnings call transcript
2023 Q4
20 Nov 23
ENTA
Earnings call transcript
2023 Q3
7 Aug 23
ENTA
Earnings call transcript
2023 Q2
8 May 23
ENTA
Earnings call transcript
2023 Q1
7 Feb 23
ENTA
Earnings call transcript
2022 Q4
21 Nov 22
ENTA
Earnings call transcript
2022 Q3
9 Aug 22
ENTA
Earnings call transcript
2022 Q2
10 May 22
ENTA
Earnings call transcript
2022 Q1
9 Feb 22
ENTA
Earnings call transcript
2021 Q4
23 Nov 21
ENTA
Earnings call transcript
2021 Q3
8 Aug 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 85.39 mm | 85.39 mm | 85.39 mm | 85.39 mm | 85.39 mm | 85.39 mm |
Cash burn (monthly) | 3.26 mm | (no burn) | 10.34 mm | 11.43 mm | 7.20 mm | 8.60 mm |
Cash used (since last report) | 7.72 mm | n/a | 24.46 mm | 27.04 mm | 17.03 mm | 20.33 mm |
Cash remaining | 77.67 mm | n/a | 60.92 mm | 58.34 mm | 68.36 mm | 65.06 mm |
Runway (months of cash) | 23.8 | n/a | 5.9 | 5.1 | 9.5 | 7.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 130 |
Opened positions | 25 |
Closed positions | 26 |
Increased positions | 45 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 214.13 bn |
Total shares | 21.48 mm |
Total puts | 1.50 k |
Total calls | 800.00 |
Total put/call ratio | 1.9 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 2.10 mm | $23.46 bn |
BLK Blackrock | 1.98 mm | $22.11 bn |
Farallon Capital Management | 1.88 mm | $20.94 bn |
Vanguard | 1.66 mm | $18.55 bn |
Farallon Capital Partners | 1.46 mm | $0.00 |
Braidwell | 1.04 mm | $11.60 bn |
Millennium Management | 1.02 mm | $11.43 bn |
NTRS Northern Trust | 959.91 k | $10.72 bn |
Krensavage Asset Management | 735.10 k | $8.18 bn |
Assenagon Asset Management | 631.63 k | $7.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Dec 23 | Luly Jay R. | Common Stock | Sell | Dispose S | No | No | 9.63 | 7,230 | 69.62 k | 806,793 |
5 Dec 23 | Mellett Paul J | Common Stock | Sell | Dispose S | No | No | 9.63 | 2,412 | 23.23 k | 93,549 |
5 Dec 23 | Yat Sun Or | Common Stock | Sell | Dispose S | No | No | 9.63 | 2,412 | 23.23 k | 370,695 |
5 Dec 23 | Scott T. Rottinghaus | Common Stock | Sell | Dispose S | No | No | 9.63 | 534 | 5.14 k | 26,466 |
5 Dec 23 | Gardiner Nathaniel S. | Common Stock | Sell | Dispose S | No | No | 9.63 | 2,412 | 23.23 k | 68,154 |
News
Oppenheimer Maintains Perform on Enanta Pharma, Lowers Price Target to $21
22 Nov 23
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
21 Nov 23
What 5 Analyst Ratings Have To Say About Enanta Pharma
21 Nov 23
HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $28
21 Nov 23
JMP Securities Maintains Outperform on Enanta Pharma, Lowers Price Target to $23
21 Nov 23
Press releases
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
22 Nov 23
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
20 Nov 23
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
13 Nov 23
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
13 Oct 23
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
17 Sep 23